Martina M.D. Flammer Sells 13,436 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Insmed Trading Up 0.0 %

NASDAQ:INSM opened at $73.26 on Wednesday. The stock’s 50 day simple moving average is $74.78 and its 200-day simple moving average is $51.24. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The firm has a market cap of $10.89 billion, a P/E ratio of -14.01 and a beta of 1.11. The company has a current ratio of 2.71, a quick ratio of 2.53 and a debt-to-equity ratio of 25.05.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The firm had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. During the same quarter in the prior year, the company earned ($1.78) EPS. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. Equities analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Barclays increased their price objective on shares of Insmed from $40.00 to $63.00 and gave the company an “overweight” rating in a research report on Wednesday, May 29th. TD Cowen upped their target price on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Truist Financial lowered their price objective on shares of Insmed from $88.00 to $85.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. StockNews.com cut shares of Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a report on Monday, September 9th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.19.

Institutional Trading of Insmed

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rafferty Asset Management LLC grew its stake in shares of Insmed by 17.4% in the fourth quarter. Rafferty Asset Management LLC now owns 321,087 shares of the biopharmaceutical company’s stock valued at $9,950,000 after buying an additional 47,563 shares in the last quarter. Kingdon Capital Management L.L.C. acquired a new stake in Insmed in the 4th quarter valued at approximately $12,551,000. Artia Global Partners LP acquired a new position in shares of Insmed during the 4th quarter valued at $2,322,000. Norges Bank acquired a new position in shares of Insmed in the 4th quarter worth $45,029,000. Finally, Clearbridge Investments LLC acquired a new stake in shares of Insmed in the first quarter worth $25,242,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.